Repligen Corporation (RGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Douglas Schenkel
Wolfe Research, LLC

All right. Good afternoon, everybody. I am Doug Schenkel with Wolfe Research. It’s my pleasure to welcome Jason Garland, Chief Financial Officer of Repligen; as well as Steven Chehames from Investor Relations. Thanks to you both for being here.

Jason Garland
CFO & Chief Compliance Officer

Thank you.

Douglas Schenkel
Wolfe Research, LLC

So Repligen is, as everybody in the room knows, but just in case, Repligen is really one of the only publicly traded pure-play bioprocessing companies available to invest in. And the company not only stands out for that reason, but there’s just a tremendous history of innovation, tuck-in acquisitions that feed into that innovation, which together has fed consistent above market growth, so we appreciate you both being here.

In terms of the agenda, I thought we would spend a couple of minutes just recapping some loose ends from Q3. It feels like that was a while ago now, but it wasn’t — I guess it wasn’t that long. But — so maybe a few things to talk about just in terms of — I think things that might be helpful to double-click on as we think about momentum into next year.

With that in mind, then I actually want to talk about the framework for next year, which I think has got a lot of focus coming off of the Q3 call, which I bet you guys have heard here and now. And then I want to get into some longer-term growth drivers, so that obviously includes ATF, but we’ll go beyond that as well.